Chief Executive Officer
Mr. Elam co-founded Rezolute, Inc. In addition to serving on the board of Rezolute, he also serves on the board of directors of Softhale in Brussels, Belgium and Savara, Inc. in Austin Texas.
Mr. Elam was previously CEO of AeroSurgical Limited, a European medical device company, which was subsequently acquired in a private transaction. Prior to AeroSurgical, Nevan had a very successful career at Nektar Therapeutics (NASDAQ: NKTR) where he served as SVP and Head of the Pulmonary Business Unit. While at Nektar, he re-shaped the pipeline and streamlined the organization. Further, during his tenure, he spun out Pearl Therapeutics to focus on treatments for asthma and COPD and Pearl was eventually acquired, in 2013, by AstraZeneca, for $1 billion. In addition, Nevan negotiated the acquisition of Aerogen, Inc. and later led a $10 million management buy out of Aerogen's Irish operations which is now a profitable business valued at more than $500 million. Finally, in 2008, he negotiated the sale of the pulmonary business unit at Nektar to Novartis for $200 million enterprise value.
Prior to his role at Nektar, Mr. Elam was CFO and co-founder of E2open, (NASDAQ: EOPN), an IT platform company serving the electronics and healthcare industries where, in addition to managing finance and corporate and business development, he established operations in five locations in Asia including Singapore, Kuala Lumpur, Taipei, Tokyo, and Seoul.
In the 1990s, Mr. Elam had a successful career at the venerable law firm of Wilson Sonsini Goodrich & Rosati in Palo Alto, California where he was a partner in the corporate practice. He worked with companies in a variety of industries including healthcare, where his clients ranged from large biotech organizations such as Genentech to small novel therapeutic companies in the US and Europe. Mr. Elam advised clients on a range of matters including debt and equity financings, FDA issues, acquisitions, partnerships and cross-border transactions. He also served clients such as Hewlett Packard and Sun Microsystems and notably, in 1997 he negotiated the sale of Steve Jobs' company, Next, to Apple.
Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School.
Mr. Kim is Chairman & CEO of Handok Inc., one of the leading pharmaceutical companies in the Republic of Korea. Mr. Kim joined Handok Inc. in 1984 and spent two years between 1984 and 1986 working at Hoechst AG in Frankfurt, Germany. Between 1991 and 2005, he served as CEO of Roussel Korea, Hoechst Marion Roussel Korea and Aventis Pharma Korea and also appointed as the Country Manager of Hoechst AG and Aventis in Korea between 1996 and 2005. In 1996, he was appointed as CEO of Handok. Mr. Kim has been serving as President of Handok Jeseok Foundation since 2014. He also has been serving as President of KDG (Korean-German Society) since 2010 and Vice President of Medium Industries Committee of KCCI (The Korea Chamber of Commerce & Industry) since 2009. Mr. Kim received an MBA at the Kelley School of Business at Indiana University in 1984 and received the award of Distinguished Alumni Fellows from Indiana University. Mr. Kim completed Advanced Management Program at the Harvard Business School in 1996. We believe Mr. Kim’s experience working with pharmaceutical companies qualifies him to serve on the Board. We believe Mr. Kim’s experience working with pharmaceutical companies qualifies him to serve on the Board.
Dr. Sung is the founder and former CEO of Genexine Inc, a KOSDAQ listed biotech company developing innovative drugs in cancer and orphan diseases. Dr. Sung currently serves as a professor at POSTECH Department of Life Sciences and founder of POSTECH- Catholic Bio Medical Institute. Dr. Sung is an expert immunologist and has published over one hundred scientific articles. He has served on editorial boards of many biological organizations and has earned numerous awards including the most recently the 49th Science Day Presidential Commendation for Science and Technology Promotion Division from KIST as remarks of Antibody fusion (hyFc) technology and gene therapy vaccine technology. Dr. Sung currently serves on the Board of the Korean Society for Molecular and Cellular Biology and The Korean Society of Medical Biochemistry and Molecular Biology both since 2003. He is also a member of the Korean Society of Virology. Dr. Sung was a former president of the Korean Association of Immunobiologists (KAI) from 2005 to 2007. We believe Dr. Sung’s scientific background qualifies him to serve on the Board.